Literature DB >> 21894525

Risk of malignancies in IgG4-related disease.

Motohisa Yamamoto1, Hiroki Takahashi, Tetsuya Tabeya, Chisako Suzuki, Yasuyoshi Naishiro, Keisuke Ishigami, Hidetaka Yajima, Yui Shimizu, Mikiko Obara, Hiroyuki Yamamoto, Tetsuo Himi, Kohzoh Imai, Yasuhisa Shinomura.   

Abstract

IgG4-related disease (IgG4-RD) is considered a systemic, chronic, and inflammatory disorder that is characterized by the enlargement of involved organs, elevated levels of IgG4, and abundant infiltration of plasmacytes with IgG4 and fibrosis in involved organs. It is necessary to differentiate IgG4-RD from malignant tumors. Recently we have looked at case reports of IgG4-RD with malignancy that was discovered at systemic screening. In this study, we analyzed the relationship between IgG4-RD and malignancies. The study subjects were 106 patients with IgG4-RD who had been referred to our hospital since April 1997. We analyzed the clinical characteristics of IgG4-RD patients who had cancer that was observed upon the initial diagnosis of IgG4-RD or that occurred during an average follow-up period of 3.1 years. Using data from national cancer registries that monitor cancer incidence in Japan, we evaluated the standardized incidence ratio (SIR) for malignancies in IgG4-RD. Malignancies were observed in 11 of the IgG4-RD patients (10.4%). The malignancies were all different and included lung cancer, colon cancer, and lymphoma. With the exception of the age at which the IgG4-RD diagnosis was made, there were no common features in patients with cancer and those without. The SIR for these malignancies in IgG4-RD was 383.0, which was higher than that for the general population. We should be cognizant of the possible existence of malignancies in patients with IgG4-RD at the time of diagnosis and during follow-up care.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21894525     DOI: 10.1007/s10165-011-0520-x

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  81 in total

Review 1.  IgG4-related disease: what urologists should know.

Authors:  Daniele Bianchi
Journal:  Int Urol Nephrol       Date:  2016-01-02       Impact factor: 2.370

2.  IgG4-related disease mimicking chalazion in the upper eyelid with skin manifestations on the trunk.

Authors:  Tiina Leivo; Sari Koskenmies; Marita Uusitalo; Olli Tynninen
Journal:  Int Ophthalmol       Date:  2015-04-03       Impact factor: 2.031

Review 3.  Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist.

Authors:  Motohisa Yamamoto; Hiroki Takahashi; Yasuhisa Shinomura
Journal:  Nat Rev Rheumatol       Date:  2013-12-03       Impact factor: 20.543

4.  Autoimmune Pancreatitis and IgG4-Related Disease: The Storiform Discovery to Treatment.

Authors:  Kazuichi Okazaki
Journal:  Dig Dis Sci       Date:  2019-09       Impact factor: 3.199

5.  [Bilateral chronic dacryoadenitis].

Authors:  F Wiesent
Journal:  Z Rheumatol       Date:  2013-09       Impact factor: 1.372

6.  Immunoglobulin G4-related disease mimicking asthma.

Authors:  Hiroshi Sekiguchi; Ryohei Horie; Timothy R Aksamit; Eunhee S Yi; Jay H Ryu
Journal:  Can Respir J       Date:  2013 Mar-Apr       Impact factor: 2.409

Review 7.  IgG4-associated cholangitis: a comprehensive review.

Authors:  Lowiek M Hubers; Lucas J Maillette de Buy Wenniger; Marieke E Doorenspleet; Paul L Klarenbeek; Joanne Verheij; Erik A Rauws; Thomas M van Gulik; Ronald P J Oude Elferink; Stan F J van de Graaf; Niek de Vries; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

8.  Autoimmune Pancreatitis.

Authors:  Gyanprakash A Ketwaroo; Sunil Sheth
Journal:  Gastroenterol Rep       Date:  2013-04-04       Impact factor: 3.651

Review 9.  [IgG4-related disease].

Authors:  J Loock; B Manger
Journal:  Z Rheumatol       Date:  2013-03       Impact factor: 1.372

Review 10.  IgG4-related hepatobiliary disease: an overview.

Authors:  Emma L Culver; Roger W Chapman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.